NANOPARTICLE FORMULATION OF BIOFLAVONOIDS FOR ENHANCED ANTI-CANCER ACTIVITY

  • S. SATHESH KUMAR Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India
  • P. SHANMUGASUNDARAM Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India
  • M. KOMALA Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India
  • B. BHARGAVI Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India
  • J. PADMAVATHY Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

Abstract

Among the natural sources, plant origin drugs constitute around 25% which includes various secondary metabolites such as bioflavonoids, alkaloids, terpenes, saponins, glucosides, and lignans. The bioflavonoids belonging to the polyphenol group shows many beneficial effects like hepatoprotective, antioxidant, antibacterial, anticancer, anti-inflammatory and antiviral. The main objective of this article is to collectively present the research data published worldwide about the anticancer activity of bioflavonoids by loading them in novel formulations. Thus, the present review explored the novel formulations of the bioflavonoids with improved pharmacokinetic properties along with the enhanced anticancer activity. The major drawback with bioflavonoids is its poor solubility and bioavailability, which restricts the usage of bioflavonoids in the treatment of cancer in the market worldwide. Novel drug delivery system seems to possess many benefits like site-specific drug delivery along with minimal side effects and improves pharmaceutical and therapeutic properties of drugs compared to a conventional dosage form of bioflavonoids. The scope for improvement of anticancer activity of bioflavonoids by incorporating in novel pharmaceutical formulations like nanoparticles is very high, and it has to be considered as a potential area of research.

Keywords: Anticancer, Bioflavonoids, Novel drug delivery system, Nanoformulations

Author Biographies

S. SATHESH KUMAR, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

Head of the Department, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

P. SHANMUGASUNDARAM, Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

Director, Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

M. KOMALA, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

Professor, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

B. BHARGAVI, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

Research Scholar, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Sciences (VISTAS), Chennai 600117, Tamil Nadu, India

References

1. Atanasov AG, Waltenberger B, Pferschy Wenzig EM, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv 2015;33:1582-614.
2. Gurnani N, Mehta D, Gupta M, Mehta BK. Natural products: source of potential drugs. Afr J Basic Appl Sci 2014;6:171-86.
3. Leopoldini M, Russo N, Chiodo S, Toscano M. Iron chelation by the powerful antioxidant flavonoid quercetin. J Agric Food Chem 2006;54:6343-51.
4. Pawar HA. Natural products as a source of lead to the design of new drugs. Nat Prod Chem Res 2014;2:156.
5. Lu J, Papp LV, Fang J, Rodriguez Nieto S, Zhivotovsky B, Holmgren A, et al. Inhibition of mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anticancer activity. Cancer Res 2006;66:4410-8.
6. Bukhari SB, Memon S, Mahroof Tahir M, Bhanger MI. Synthesis, characterization and antioxidant activity copper-quercetin complex. Spectrochim Acta A Mol Biomol Spectrosc 2009;71:1901-6.
7. Khnau J. The flavonoids a class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 1976;24:117-91.
8. Kumar S, Pandey AK. Antioxidant, lipo-protective and antibacterial activities of phytoconstituents present in Solanum xanthocarpum root. Int Rev Biophys Chem 2012;3:42-7.
9. Hertog MG, Kromhout D, Aravanis C. Flavonoid intake and long term risk of coronary heart disease and cancer in seven countries study. Arch Int Med 1995;155:381-6.
10. Ferrndiz ML, Nair AG, Alcaraz MJ. Inhibition of sheep platelet arachidonate metabolism by flavonoids from spanish and Indian medicinal herbs. Pharmazie 1990;45:206-8.
11. Ferrndiz ML, Alcaraz MJ. Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoids. Agents Actions 1991;32:283-8.
12. Stefani ED, Boffetta P, Deneo Pellegrini H, Mendilaharsu M, Carzoglio JC, Ronco A, et al. Dietary antioxidants and lung cancer risk: a case-control study in Uruguay. Nutr Cancer 1999;34:100-10.
13. Alcaraz MJ, Ferrandiz ML. Modification of arachidonic metabolism by flavonoids. J Ethnopharmacol 1987;21:209-29.
14. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997;57:2916-21.
15. Laughton MJ, Evans PJ, Moroney MA, Hoult JR, Halliwell B. Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol 1991;42:1673-81.
16. Al Rashid MH, Deepak Bharadwaj PVP, Majumder S, Mandal V, Pal M, Mandal SC, et al. Antioxidant and anticancer activity of extract and fractions obtained from diospyros melanoxylon roxb. Leaves and correlation with their polyphenolic profiles. Int J Pharm Pharm Sci 2018;10:6-16.
17. Madhu CS, Sharada AC. Evaluation of heamagglutination and anti-cancer potential from indian dietary plants. Int J Pharm Pharm Sci 2018;10:105–8.
18. Neerugatti DB, GR Battu, R Bandla. Cytotoxicity activity of some Indian medicinal plants. Int J Curr Pharm Res 2016;8:57–9.
19. Devi KP, Balan DJ. Flavonoids and their anti-cancer effect is targeting the major signalling pathways involved. In: Recent advances in the molecular mechanism of flavonoids. Houston, Texas: Studium Press (India Pvt. Ltd.); 2018. p. 1-22.
20. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 2000;87:595-600.
21. Hegarty VM, May HM, Khaw KT. Tea drinking and bone mineral density in older women. Am J Clin Nutr 2000;71:1003-7.
22. Di Carlo G, Autore G, Izzo AA, Maiolino P, Mascolo N, Viola P, et al. Inhibition of intestinal motility and secretion by flavonoids in mice and rats: structure-activity relationships. J Pharm Pharmacol 1993;45:1054-9.
23. Wang HK, Xia Y, Yang ZY, Natschke SL, Lee KH. Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Adv Exp Med Biol 1998;439:191-225.
24. Wild C, Fasel J. Effect of a flavonoid on the capillary resistance of the rectal mucosa in hepatic cirrhosis. Am J Proctol 1969;20:60-3.
25. Ravishankar D, Rajora AK, Greco F, Osborn HM. Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol 2013;45:2821-31.
26. Li S, Pan MH, Lai CS, Lo CY, Dushenkov S, Ho CT. Isolation and syntheses of poly-methoxyflavones and hydroxylated polymethoxyflavones as inhibitors ofHL-60 cell lines. Bioorg Med Chem 2007;15:3381-9.
27. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci Biotechnol Biochem 1999;63:896-9.
28. Saewan N, Koysomboon S, Chantrapromma K. Anti-tyrosinase and anti-cancer activities of flavonoids from Blumea balsamifera DC. J Med Plants Res 2011;5:1018-25.
29. Zhou JR, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK, et al. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 1998;58:5231-8.
30. Veeramuthu D, Raja WR, Al-Dhabi WA, Savarimuthu I. Flavonoids: anticancer properties. In: Flavonoids-From biosynthesis to human health; 2017. p. 287-303.
31. Saravanan D, Maheswaran A, Padmavathy J, Angel P. Molecular mechanism of flavonoids on cardiac diseases. In: Devi PK. editors. Recent advances in the molecular mechanism of flavonoids. Houston, TX: Studium Press (India Pvt. Ltd.); 2018. p. 183-201.
32. Bhagwat RR, Vaidhya IS. Novel drug delivery systems: an overview. Int J Pharm Sci Res 2013;4:970-82.
33. Saha C, Kaushik A, Das A, Pal S, Majumder D. Anthracycline drugs on modified surface of quercetin-loaded polymer nanoparticles: a dual drug delivery model for cancer treatment. PLoS One 2016;11:e0155710.
34. Devendiran RM, Chinnaiyan SK, Yadav NK, Ramanathan G, Singaravelu S, Perumal SP, et al. Facile synthesis and evaluation of quercetin reduced and dextran sulphate stabilized gold nanoparticles decorated with folic acid for active targeting against breast cancer. RSC Adv 2016;4:1-14.
35. Pandey SK, Patel DK, Thakur R, Mishra DP, Maiti P, Haldar C, et al. Anti-cancer evaluation of quercetin embedded PLA nanoparticles synthesized by emulsified nanoprecipitation. Int J Biol Macromol 2015;75:521-9.
36. Sahu S, Saraf S, Kaur CD, Saraf S. Biocompatible nanoparticles for sustained topical delivery of anticancer phytoconstituent quercetin. Pak J Biol Sci 2013;16:601-9.
37. Jalil Rashedi, Amir Ghorbani Haghjo, Mehran Mesgari Abbasi, Ali Dastranj Tabrizi, Shabdi Yaquobi, Davoud Sanajou, et al. Anti-tumor effect of quercetin loaded chitosan nanoparticles on induced colon cancer in wistar rats. Adv Pharm Bull 2019;9:409-15.
38. Shivsharan B, Baburao D, Chandakavathe N. Anti-diabetic potential of Flavonoids and their molecular mechanisms. In: Devi KP. editor. Recent Advances in the Molecular Mechanism of Flavonoids. Houston, Texas: Studium Press (India Pvt. Ltd.); 2018. p. 104-39.
39. Naeimi AF, Alizadeh M. Antioxidant properties of the flavonoid fisetin: An updated review of in vivo and in vitro studies. Trends Food Sci Tech 2017;70:34-44.
40. Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ, et al. Distinctive antioxidant and anti-inflammatory effects of flavonols. J Agric Food Chem 2006;54:9798-804.
41. Hendriks JJ, de Vries HE, van der Pol SM, van den Berg TK, van Tol EA, Dijkstra CD, et al. Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. Biochem Pharmacol 2003;65:877-85.
42. Inouye Y, Yamaguchi K, Take Y, Nakamura S. Inhibition of avian myeloblastosis virus reverse transcriptase by flavones and isoflavones. J Antibiot (Tokyo) 1989;42:1523-5.
43. Chu SC, Hsieh YS, Lin JY. Evaluation of the anti-herpetic activity of methanol seed extract and fractions of securigera securidaca in vitro. J Nat Prod 2013;55:179-83.
44. Lall RK, Adhami VM, Mukhtar H. Dietary flavonoid fisetin for cancer prevention and treatment. Mol Nutr Food Res 2016;60:1396-405.
45. Pal HC, Pearlman RL, Afaq F. Fisetin and its role in chronic diseases. Adv Exp Med Biol 2016;928:213-44.
46. Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, Wang QJ, et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 2010;285:40461-71.
47. Kim HJ, Kim SK, Kim BS, Lee SH, Park YS, Park BK, et al. Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J Agric Food Chem 2010;58:8643-50.
48. Kim DY, Park MW, Yuan HD, Lee HJ, Kim SH, Chung SH, et al. Compound K induces apoptosis via CAMK-IV/AMPK pathways in HT-29 colon cancer cells. J Agric Food Chem 2009;57:10573-8.
49. Ragelle H, Crauste Manciet S, Seguin J, Brossard D, Scherman D, Arnaud P, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm 2012;427:452-9.
50. Bothiraja C, Yojana BD, Pawar AP, Shaikh KS, Thorat UH. Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study. Expert Opin Drug Delivery 2014;11:17-29.
51. Meghwal M, Sahu CK. Soy isoflavonoids as a nutraceutical for human health: an update. J Cell Sci Ther 2015;6:1000194.
52. Suthar AC, Banavalikar MM, Biyani MK. Pharmacological activities of genistein, an isoflavone from soy (Glycine max): Part II-anti-cholesterol activity, effects on osteoporosis and menopausal symptoms. Indian J Exp Biol 2001;39:520-5.
53. Zhang H, Liu G, Zeng X, Wu Y, Yang C, Mei L, et al. Fabrication of genistein-loaded biodegradable TPGS-b-PCL nanoparticles for improved therapeutic effects in cervical cancer cells. Int J Nanomed 2015;10:2461-73.
54. Kumar SK, Manju V. Pharmacological applications of isrhamnetin: a short review. Int J Trend Sci Res Dev 2017;1:672-8.
55. Ma G, Yang C, Qu Y, Wei H, Zhang T, Zhang N, et al. The flavonoid component isorhamnetin in vitro inhibits proliferation and induces apoptosis in eca-109 cells. Chem Biol Interact 2007;167:153-60.
56. Lee K, Kwon M, Baek I, Kim H, Lee H, Park H, et al. Ant proliferation effects of isorhamnetin isolated from Persicaria thunbergii on cancer cell lines. Nat Prod Sci 2006;12:214-26.
57. Steffen Y, Gruber C, Schewe T, Sies H. Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys 2008;469:209-19.
58. Settu K, Vaiyapuri M. Formulation and evaluation of isorhamnetin loaded poly lactic-co-glycolic acid nanoparticles. Asian J Pharm Clin Res 2017;10:177-81.
59. Yang RY, Lin S, Kuo G. Content and distribution of flavonoids among 91 edible plant species. Asia Pac J Clin Nutr 2008;17 Suppl 1:275-9.
60. Franke AA, Custer LJ, Arakaki C, Murphy SP. Vitamin C and flavonoid levels of fruits and vegetables consumed in Hawaii. Food Compost Anal 2004;17:1-35.
61. Andrade Cetto A, Wiedenfeld H, Revilla MC, Sergio IA. Hypoglycemic effect of equisetum myriochaetum aerial parts on streptozotocin-diabetic rats. J Ethnopharmacol 2000;72:129-33.
62. J M Calderon Montano, E Burgos Moron, C Perez Guerrero, M Lopez Lazaro. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem 2011;11:298-344.
63. Luo H, Jiang B, Li B, Li Z, Jiang BH, Chen YC, et al. Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability. Int J Nanomed 2012;7:3951-9.
64. Raghavan BS, Kondath S, Anantanarayanan R, Rajaram R. Kaempferol mediated synthesis of gold nanoparticles and their cytotoxic effects on MCF-7 cancer cell line. Process Biochem 2015;50:1966-76.
65. Chahar MK, Sharma N, Dobhal MP, Joshi YC. Flavonoids: a versatile source of anticancer drugs. Pharmacogn Rev 2011;5:1-2.
66. Majumdar D, Jung KH, Zhang H, Nannapaneni S, Wang X, Amin AR, et al. Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. Cancer Prev Res (Phila) 2014;7:65-73.
67. Gurushankar K, Gohulkumar M, Prasad NR, Krishnakumar N. Synthesis, characterization and in vitro anticancer evaluation of hesperetin-loaded nanoparticles in human oral carcinoma(KB) cells. Adv Nat Sci Nanosci Nanotechnol 2014;5:15006.
68. Le Gall G, DuPont MS, Mellon FA, Davis AL, Collins GJ, Verhoeyen ME, et al. Characterization and content of flavonoid glycosides in genetically modified tomato (Lycopersicon esculentum) fruits. J Agric Food Chem 2003;51:2438-46.
69. Wang H, Nair MG, Strasburg GM, Booren AM, Gray JI. Antioxidant polyphenols from tart cherries (Prunus cerasus). J Agric Food Chem 1999;47:840-4.
70. Chang H, Mi M, Ling W, Zhu J, Zhang Q, Wei N, et al. Structurally related cytotoxic effects of flavonoids on human cancer cells in vitro. Arch Pharm Res 2008;31:1137-44.
71. Kanno S, Tomizawa A, Hiura T, Osanai Y, Shouji A, Ujibe M, et al. Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull 2005;28:527-30.
72. Kim JH, Lee JK. Naringenin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on burkitt’s lymphoma cells. Arch Pharm Res 2015;38:2042-8.
73. Lee YS, Reidenberg MM. A method for measuring naringenin in biological fluids and its disposition from grapefruit juice by man. Pharmacology 1998;56:314-7.
74. Middleton E Jr, Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol 1992;43:1167-79.
75. Rajadurai M, Prince PS. Naringin ameliorates mitochondrial lipid peroxides, antioxidants and lipids in isoproterenol-induced myocardial infarction in wistar rats. Phytother Res 2009;23:358-62.
76. Rimm EB, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 1996;125:384-9.
77. Al-Rejaie SS, Abuohashish HM, Al-Enazi MM, Al-Assaf AH, Parmar MY, Ahmed MM, et al. Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol 2013;19:5633-44.
78. Winarti L, Sari LO, Nugroho AE. Naringenin loaded chitosan nanoparticles formulation and it’s in vitro evaluation against T47D breast cancer cell line. Indones J Pharm 2015;26:147-57.
79. Parashar P, Rathor M, Dwivedi M, Saraf SA. Hyaluronic acid decorated naringenin nanoparticles: appraisal of the chemopreventive and curative potential for lung cancer. Pharmaceutics 2018;10:E33.
80. Kamalakkannan N, Prince PS. Antihyperglycaemic and antioxidant effect of rutin, a polyphenolic flavonoid, in streptozotocin-induced diabetic wistar rats. Basic Clin Pharmacol Toxicol 2006;98:97-103.
81. Luo H, Jiang BH, King SM, Chen YC. Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer 2008;60:800-9.
82. Padmavathy J, Sathesh Kumar S. Bioflavonoids with anticancer activity and their novel formulations. Asian J Pharm Clin Res 2018;11:1–6.
83. Asfour MH, Mohsen AM. Formulation and evaluation of pH-sensitive rutin nanospheres against colon carcinoma using HCT-116 cell line. J Adv Res 2018;9:17-26.
84. Ahmad M, Sahabjada AS, Akhtar J, Hussain A, Badaruddeen M, Arshad M, et al. Development of a new rutin nanoemulsion and its application on prostate carcinoma PC3 cell line. EXCLI J 2017;16:810-23.
Statistics
51 Views | 40 Downloads
Citatons
How to Cite
KUMAR, S. S., SHANMUGASUNDARAM, P., KOMALA, M., BHARGAVI, B., & PADMAVATHY, J. (2020). NANOPARTICLE FORMULATION OF BIOFLAVONOIDS FOR ENHANCED ANTI-CANCER ACTIVITY. International Journal of Applied Pharmaceutics, 12(5), 29-35. https://doi.org/10.22159/ijap.2020v12i5.38425
Section
Review Article(s)